Sabal Trust CO Increases Position in Amgen Inc. (AMGN)
Sabal Trust CO boosted its position in shares of Amgen Inc. (NASDAQ:AMGN) by 6.0% during the second quarter, Holdings Channel reports. The institutional investor owned 137,726 shares of the medical research company’s stock after buying an additional 7,842 shares during the period. Amgen accounts for about 2.5% of Sabal Trust CO’s investment portfolio, making the stock its 21st largest position. Sabal Trust CO’s holdings in Amgen were worth $23,720,000 as of its most recent SEC filing.
Other large investors have also recently made changes to their positions in the company. Rathbone Brothers plc boosted its stake in shares of Amgen by 2.9% in the first quarter. Rathbone Brothers plc now owns 41,341 shares of the medical research company’s stock worth $6,783,000 after buying an additional 1,169 shares in the last quarter. CENTRAL TRUST Co boosted its stake in shares of Amgen by 1.2% in the first quarter. CENTRAL TRUST Co now owns 56,883 shares of the medical research company’s stock worth $9,333,000 after buying an additional 699 shares in the last quarter. Manning & Napier Advisors LLC boosted its stake in shares of Amgen by 4.8% in the first quarter. Manning & Napier Advisors LLC now owns 74,381 shares of the medical research company’s stock worth $12,202,000 after buying an additional 3,378 shares in the last quarter. Fulton Bank N.A. boosted its stake in shares of Amgen by 12.0% in the first quarter. Fulton Bank N.A. now owns 10,793 shares of the medical research company’s stock worth $1,771,000 after buying an additional 1,158 shares in the last quarter. Finally, West Oak Capital LLC boosted its stake in shares of Amgen by 2.5% in the first quarter. West Oak Capital LLC now owns 10,227 shares of the medical research company’s stock worth $1,678,000 after buying an additional 250 shares in the last quarter. Institutional investors and hedge funds own 79.12% of the company’s stock.
Shares of Amgen Inc. (AMGN) traded up 0.16% during mid-day trading on Friday, reaching $168.08. The company’s stock had a trading volume of 921,151 shares. The company’s 50-day moving average price is $174.19 and its 200-day moving average price is $167.96. The stock has a market capitalization of $122.64 billion, a P/E ratio of 15.31 and a beta of 1.35. Amgen Inc. has a 12-month low of $133.64 and a 12-month high of $184.21.
Amgen (NASDAQ:AMGN) last issued its earnings results on Tuesday, July 25th. The medical research company reported $3.27 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.11 by $0.16. The company had revenue of $5.81 billion for the quarter, compared to the consensus estimate of $5.67 billion. Amgen had a return on equity of 29.85% and a net margin of 35.46%. The firm’s quarterly revenue was up 2.1% on a year-over-year basis. During the same quarter last year, the company earned $2.84 EPS. On average, equities research analysts forecast that Amgen Inc. will post $12.57 earnings per share for the current fiscal year.
The firm also recently announced a quarterly dividend, which will be paid on Friday, September 8th. Investors of record on Thursday, August 17th will be paid a dividend of $1.15 per share. This represents a $4.60 annualized dividend and a yield of 2.74%. The ex-dividend date of this dividend is Tuesday, August 15th. Amgen’s dividend payout ratio (DPR) is presently 41.93%.
TRADEMARK VIOLATION WARNING: This article was first reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this article on another publication, it was illegally copied and reposted in violation of international copyright and trademark legislation. The original version of this article can be read at https://www.thecerbatgem.com/2017/08/18/sabal-trust-co-increases-position-in-amgen-inc-amgn.html.
AMGN has been the topic of a number of research reports. Sanford C. Bernstein restated a “market perform” rating and issued a $178.00 price objective on shares of Amgen in a research note on Tuesday, April 25th. Cowen and Company restated a “buy” rating and issued a $209.00 price objective on shares of Amgen in a research note on Thursday, April 27th. Robert W. Baird restated a “neutral” rating and issued a $165.00 price objective on shares of Amgen in a research note on Friday, April 28th. Mizuho set a $195.00 price objective on Amgen and gave the company a “buy” rating in a research note on Saturday, May 6th. Finally, Oppenheimer Holdings, Inc. set a $189.00 price objective on Amgen and gave the company a “buy” rating in a research note on Tuesday, May 9th. One analyst has rated the stock with a sell rating, twelve have issued a hold rating, twelve have issued a buy rating and two have issued a strong buy rating to the stock. Amgen has an average rating of “Buy” and a consensus price target of $186.64.
In related news, SVP Cynthia M. Patton sold 2,922 shares of Amgen stock in a transaction that occurred on Wednesday, May 24th. The stock was sold at an average price of $154.40, for a total transaction of $451,156.80. Following the sale, the senior vice president now owns 24,214 shares of the company’s stock, valued at approximately $3,738,641.60. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 0.20% of the stock is currently owned by company insiders.
Amgen Company Profile
Amgen Inc is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as KYPROLIS (carfilzomib), Vectibix (panitumumab), Nplate (romiplostim), Repatha (evolocumab), BLINCYTO (blinatumomab), IMLYGIC (talimogene laherparepvec) and Corlanor (ivabradine).
Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen Inc. (NASDAQ:AMGN).
Receive News & Stock Ratings for Amgen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen Inc. and related stocks with our FREE daily email newsletter.